@Tooheys8
Happy to be corrected, I suspect it is basically because it provides 'immediate access' to a much larger patient 'data-set' to move the 'breadth' of the testing/assessments forward far more quickly than waiting (and paying) for access to 'fresh' new-samples as they become available...
Reading between the lines, it seems exosomes have a 'shelf-life' as such, so will basically required UQ & IIQ to 'revert' to basically acquiring access to 'fresh samples' on an ongoing basis to move the test forward (get 'statistical runs' on the board with a significant sample size), collate and then, present to industry, hence the H2FY24 delay-statement...
ML
@Tooheys8 Happy to be corrected, I suspect it is basically...
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.5¢ |
Change
-0.010(1.87%) |
Mkt cap ! $48.31M | |||
| Open | High | Low | Value | Volume |
| 53.0¢ | 53.5¢ | 52.5¢ | $12.70K | 24.00K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7685 | 52.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 53.5¢ | 6500 | 1 |
View Market Depth
| Last trade - 15.42pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
52.5¢ |
Change
-0.010 ( 2.78 %) |
||||
| Open | High | Low | Volume | ||
| 53.0¢ | 53.0¢ | 52.5¢ | 6712 | ||
| Last updated 11.43am 26/04/2024 ? | |||||
| IIQ (ASX) Chart |